Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults

AIDS. 2010 Jul 31;24(12):1958-61. doi: 10.1097/QAD.0b013e32833c3251.

Abstract

In this 13-week, open-label, randomized study of the anti-inflammatory salsalate versus usual care, there were no significant improvements in flow-mediated dilation of the brachial artery, endothelial activation, inflammation or coagulation markers, homeostasis model assessment of insulin resistance or lipoproteins with salsalate or between groups in virologically suppressed, HIV-infected adults on antiretrovirals. Tinnitus and transaminitis occurred frequently in the salsalate group. Dose reduction due to toxicities encountered and low level of inflammation may explain these results.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Brachial Artery / physiopathology*
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology*
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / physiopathology*
  • Humans
  • Insulin Resistance
  • Male
  • Salicylates / administration & dosage*
  • Salicylates / adverse effects

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Salicylates
  • salicylsalicylic acid